Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Oxalate nephropathy in ataxia telangiectasia - A case report.
Perera LR, Chung EYM, Roxburgh S. Perera LR, et al. Among authors: roxburgh s. Nephrology (Carlton). 2023 Aug;28(8):468-469. doi: 10.1111/nep.14173. Epub 2023 May 16. Nephrology (Carlton). 2023. PMID: 37191056 No abstract available.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Treatment decision-making and care among older adults with kidney failure: protocol for a multicentre, prospective observational cohort study with nested substudies and linked qualitative research (the Elderly Advanced CKD Programme).
Siriwardana A, Gray NA, Makris A, Li CK, Yong K, Mehta Y, Ramos J, Di Tanna GL, Gianacas C, Addo IY, Roxburgh S, Naganathan V, Foote C, Gallagher M. Siriwardana A, et al. Among authors: roxburgh s. BMJ Open. 2022 Dec 29;12(12):e066156. doi: 10.1136/bmjopen-2022-066156. BMJ Open. 2022. PMID: 36581411 Free PMC article.
A globally relevant change taxonomy and evidence-based change framework for land monitoring.
Lucas RM, German S, Metternicht G, Schmidt RK, Owers CJ, Prober SM, Richards AE, Tetreault-Campbell S, Williams KJ, Mueller N, Tissott B, Chua SMT, Cowood A, Hills T, Gunawardana D, McIntyre A, Chognard S, Hurford C, Planque C, Punalekar S, Clewley D, Sonnenschein R, Murray NJ, Manakos I, Blonda P, Owers K, Roxburgh S, Kay H, Bunting P, Horton C. Lucas RM, et al. Among authors: roxburgh s. Glob Chang Biol. 2022 Nov;28(21):6293-6317. doi: 10.1111/gcb.16346. Epub 2022 Sep 1. Glob Chang Biol. 2022. PMID: 36047436 Free PMC article.
70 results